A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study

References

• Scholl P R, Geha R S. MHC class II signaling in B-cell activation. Immunol Today 1994; 15: 418–422
   PubMedGoogle Scholar
• Dechant M, Bruenke J, Valerius T. HLA class II antibodies for the therapy of hematologic malignancies. Semin Oncol 2003; 30: 465–475
   PubMed Web of Science ®Google Scholar
• deNardo G L, O'Donnell R T, Rose L M, Mirick G R, Kroger L A, DeNardo S J. Milestones in the development of Lym-1 therapy. Hybridoma 1999; 18: 1–11
   PubMed Web of Science ®Google Scholar
• Gingrich R D, Dahle C E, Hoskins K F, Senneff M J. Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes. Blood 1990; 75: 2375–2387
   PubMed Web of Science ®Google Scholar
• Kostelny S A, Link B K, Tso J Y, Vasquez M, Jorgensen B H, Wang H, et al. Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 2001; 93: 556–565
   PubMed Web of Science ®Google Scholar
• Shi J D, Bullock C, Hall W C, Wescott V, Wang H, Levitt D J, et al. In vivo pharmacodynamic effects of Hu1D10 (Remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. Leuk Lymphoma 2002; 43: 1303–1312
   PubMed Web of Science ®Google Scholar
• Link B K, Kahl B, Czuczman M S, Powell B L, Bartlett N, Leonard J P, et al. A phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody, in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma. Blood 2001; 98: 606a
   Web of Science ®Google Scholar
• Link B K, Wang H, Byrd J C, Leonhard J B, Davis T A, Flinn I, et al. Phase I study of Hu1D10 monoclonal antibody (Remitogen) in patients with B-cell lymphoma. Proc Am Soc Clin Oncol 2001; 1135, abstract
   Google Scholar
• Link B K, Wang H, Byrd J C, Leonhard J B, Davis T A, Flinn I, et al. Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen (Hu1D10). Blood 2001; 98: 244b
   PubMed Web of Science ®Google Scholar
• Elsässer D, Valerius T, Repp R, Weiner G J, Deo Y, Kalden J R, et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with G-CSF. Blood 1996; 87: 3803–3812
   PubMed Web of Science ®Google Scholar
• Würflein D, Dechant M, Stockmeyer B, Tutt A L, Hu P, Repp R, et al. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B-cells. Cancer Res 1998; 58: 3051–3058
   PubMed Web of Science ®Google Scholar
• Di Carlo E, Forini G, Lollini P L, Colombo M P, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001; 97: 339–345
   PubMed Web of Science ®Google Scholar
• Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden J R, et al. Neutrophils express the high affinity receptor for IgG (FcγRI; CD64) after in vivo application of rhG-CSF. Blood 1991; 78: 885–889
   PubMed Web of Science ®Google Scholar
• Valerius T, Repp R, de Wit T PM, Berthold S, Platzer E, Kalden J R, et al. Involvement of the high affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 1993; 82: 931–939
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri F J, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, et al. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003; 9: 5866–5873
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri F J, Jupudy V, Reising S, Repasky E A, Czuczman M S. Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma 2005; 46: 1775–1784
   PubMed Web of Science ®Google Scholar
• Vaickus L, Biddle W, Cemerlic D, Foon K A. Interferon-γ augments Lym-1-dependent, granulocyte-mediated tumor cell lysis. Blood 1990; 75: 2408–2416
   PubMed Web of Science ®Google Scholar
• Ottonello L, Epstein A L, Dapino P, Barbera P, Morone P, Dallegri F. Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony- stimulating factor: intervention of FcγRII (CD32), CD11b-CD18 intergrins, and CD66b glycoproteins. Blood 1999; 93: 3505–3511
   PubMed Web of Science ®Google Scholar
• van der Kolk L E, Grillo-Lopez A J, Baars J W, van Oers M H. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia 2003; 17: 1658–1664
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Schiller M, Repp R, Lorenz H M, Kalden J R, Gramatzki M, et al. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor (G-CSF)-primed effector cells and Hu1D10 – a humanized HLA DR antibody. Br J Haematol 2002; 118: 959–967
   PubMed Web of Science ®Google Scholar
• Lin T S, Stock W, Lucas M S, Porcu P, et al. A phase I dose escalation study of apolizumab (Hu1D10) using a stepped up dosing schedule in patients with chronic lymphocytic leukemia and acute lymphocytic leukemia. Blood 2002; 100: 802a
   Web of Science ®Google Scholar
• Nagy Z A, Hubner B, Löhning C, Rauchenberger R, Reiffert S, Thomassen-Wolf E, et al. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat Med 2002; 8: 801–807
   PubMed Web of Science ®Google Scholar
• van der Kolk L E, Grillo-Lopez A J, Baars J W, Hack C E, van Oers M HJ. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001; 115: 807–811
   PubMed Web of Science ®Google Scholar
• Diehl L F, Ketchum L H. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97
   PubMed Web of Science ®Google Scholar
• Robak T, Blasinska-Morawiec M, Krykowski E, Hellmann A, Konopka L. Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukemia treated with 2-chlorodeoxyadenosine (cladribine). Eur J Haematol 1997; 58: 109–113
   PubMed Web of Science ®Google Scholar
• Dechant M, Vidarsson G, Stockmeyer B, Repp R, Glennie M J, Gramatzki M, et al. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 2002; 100: 4574–4580
   PubMed Web of Science ®Google Scholar